ALNY : Alnylam Pharmaceuticals stock forecast, predictions, and share price target 2025 - 2026 - 2030 - 2035 with analysis
| year | Average | Low | High | Change from close on 2025-06-17 |
|---|---|---|---|---|
| 2025 | $345.77 | $326.55 | $364.4 | 12.0% |
| 2026 | $404.29 | $373.54 | $425.13 | 30.96% |
| 2027 | $422.63 | $403.33 | $428.86 | 36.9% |
| 2028 | $334.6 | $299.88 | $395.01 | 8.39% |
| 2029 | $336.93 | $303.9 | $366.65 | 9.14% |
| 2030 | $326.03 | $275.95 | $402.69 | 5.61% |
| 2031 | $348.18 | $324.72 | $389.25 | 12.79% |
| 2032 | $311.62 | $292.34 | $322.06 | 0.94% |
| 2033 | $253.23 | $205.15 | $287.03 | -17.97% |
| 2034 | $337.92 | $218.55 | $371.81 | 9.46% |
| 2035 | $368.23 | $361.48 | $377.22 | 19.28% |
The 33 Wall Street analysts offering Alnylam Pharmaceuticals stock forecast in the last 6 months have average price target of
$340.55 with a high forecast of $500.0 and a low forecast of $268.0.
The average Alnylam Pharmaceuticals stock forecast represents a 10.31%
increase from the last price of $308.709991455078.
For Alnylam Pharmaceuticals stock forecast for 2025, 6 predictions are offered for each month of 2025 with average Alnylam Pharmaceuticals stock
forecast of $345.77, a high forecast of $364.4, and a low forecast of $326.55.
The average Alnylam Pharmaceuticals stock forecast 2025 represents a 12.0%
increase from the last price of $308.709991455078.
For Alnylam Pharmaceuticals stock forecast for 2026, 12 predictions are offered for each month of 2026 with average Alnylam Pharmaceuticals stock
forecast of $404.29, a high forecast of $425.13, and a low forecast of $373.54.
The average Alnylam Pharmaceuticals stock forecast 2026 represents a 30.96%
increase from the last price of $308.709991455078.
For Alnylam Pharmaceuticals stock forecast for 2028, 12 predictions are offered for each month of 2028 with average Alnylam Pharmaceuticals stock
forecast of $334.6, a high forecast of $395.01, and a low forecast of $299.88.
The average Alnylam Pharmaceuticals stock forecast 2028 represents a 8.39%
increase from the last price of $308.709991455078.
For Alnylam Pharmaceuticals stock forecast for 2030 (5 year), 12 predictions are offered for each month of 2030 with average Alnylam Pharmaceuticals stock
forecast of $326.03, a high forecast of $402.69, and a low forecast of $275.95.
The average Alnylam Pharmaceuticals stock forecast 2030 represents a 5.61%
increase from the last price of $308.709991455078.
For Alnylam Pharmaceuticals stock forecast 2031, 12 predictions are offered for each month of 2031 with average Alnylam Pharmaceuticals stock
forecast of $348.18, a high forecast of $389.25, and a low forecast of $324.72.
The average Alnylam Pharmaceuticals stock forecast 2031 represents a 12.79%
increase from the last price of $308.709991455078.
For Alnylam Pharmaceuticals stock forecast for 2035 (10 year), 6 predictions are offered for each month of 2035 with average Alnylam Pharmaceuticals stock
forecast of $368.23, a high forecast of $377.22, and a low forecast of $361.48.
The average Alnylam Pharmaceuticals stock forecast 2035 represents a 19.28%
increase from the last price of $308.709991455078.
Please, see more forecasts below.
ALNY : Alnylam Pharmaceuticals stock forecast by Wall Street Analysts
The average Alnylam Pharmaceuticals stock forecast from last 6 month is $340.55, and this show a 4.28% increase in average from the prior price target of the each prediction. Also, this average forecast of $340.55 represents a 14.71% increase from the past average forecast of $296.87, 6 months ago from 55 wall street analysts.
| Date | Firm | previous price target | current price target | current rating |
|---|---|---|---|---|
| 2025-06-12 | JP Morgan | $330.0000 | $338.0000 | Overweight |
| 2025-05-02 | Chardan Capital | $300.00 | $325 | Buy |
| 2025-05-02 | UBS | $331.0000 | $349.0000 | Buy |
| 2025-04-11 | Morgan Stanley | $284.00 | $268 | Equal-Weight |
| 2025-04-09 | Needham | $320.00 | $320 | Buy |
| 2025-04-02 | HC Wainwright & Co. | $500.0000 | $500 | Buy |
| 2025-03-31 | Stifel | $300.0000 | $345 | Buy |
| 2025-03-31 | Redburn Atlantic | $353.0000 | Buy | |
| 2025-03-31 | Scotiabank | $338.00 | $342.0000 | Sector Outperform |
| 2025-03-24 | JP Morgan | $280.00 | $328.0000 | Overweight |
| 2025-03-21 | Needham | $320.0000 | $320 | Buy |
| 2025-03-21 | Chardan Capital | $300.00 | $300.00 | Buy |
| 2025-03-21 | B of A Securities | $302.0000 | $325 | Buy |
| 2025-03-21 | Wells Fargo | $275.0000 | $287.0000 | Equal-Weight |
| 2025-03-21 | Scotiabank | $300.00 | $338 | Sector Outperform |
| 2025-03-21 | RBC Capital | $310.0000 | $330.0000 | Outperform |
| 2025-03-21 | Canaccord Genuity | $385.00 | $390.0000 | Buy |
| 2025-03-21 | Citigroup | $338.0000 | $351.0000 | Buy |
| 2025-03-11 | JP Morgan | $272.0000 | $280.0000 | Neutral |
| 2025-02-26 | RBC Capital | $310.0000 | $310 | Outperform |
| 2025-02-26 | Chardan Capital | $300.00 | $300.00 | Buy |
| 2025-02-26 | Needham | $320.00 | $320 | Buy |
| 2025-02-25 | HC Wainwright & Co. | $400.0000 | $500.0000 | Buy |
| 2025-02-24 | HC Wainwright & Co. | $400.00 | $500.0000 | Buy |
| 2025-02-18 | Canaccord Genuity | $384.0000 | $385.0000 | Buy |
| 2025-02-14 | Needham | $320.00 | $320 | Buy |
| 2025-02-14 | Morgan Stanley | $275.0000 | $284 | Equal-Weight |
| 2025-02-14 | Scotiabank | $310.00 | $300.0000 | Sector Outperform |
| 2025-02-11 | RBC Capital | $300.00 | $300.0000 | Outperform |
| 2025-01-21 | RBC Capital | $300.00 | $300 | Outperform |
| 2025-01-13 | Needham | $320.00 | $320 | Buy |
| 2025-01-13 | HC Wainwright & Co. | $400.00 | $400 | Buy |
| 2025-01-07 | Bernstein | $314.0000 | $310.0000 | Outperform |
| 2024-11-18 | HC Wainwright & Co. | $400.0000 | $400 | Buy |
| 2024-11-18 | Piper Sandler | $296.0000 | $296 | Overweight |
| 2024-11-12 | Wolfe Research | Underperform | ||
| 2024-11-04 | HC Wainwright & Co. | $400.00 | $400.00 | Buy |
| 2024-11-01 | Raymond James | $275.0000 | $298 | Outperform |
| 2024-11-01 | RBC Capital | $300.00 | $300.00 | Outperform |
| 2024-11-01 | Scotiabank | $305.00 | $310.0000 | Sector Outperform |
| 2024-11-01 | Barclays | $295.00 | $329.0000 | Overweight |
| 2024-11-01 | Canaccord Genuity | $366.00 | $384.0000 | Buy |
| 2024-11-01 | Chardan Capital | $300.00 | $300.00 | Buy |
| 2024-11-01 | Needham | $320.00 | $320.00 | Buy |
| 2024-10-21 | TD Cowen | $282.00 | $371.0000 | Buy |
| 2024-10-18 | HC Wainwright & Co. | $400.00 | $400.00 | Buy |
| 2024-10-16 | Scotiabank | $305.0000 | Sector Outperform | |
| 2024-10-14 | B of A Securities | $307.00 | $314 | Buy |
| 2024-10-11 | Cantor Fitzgerald | $220.00 | $220.0000 | Neutral |
| 2024-10-11 | Chardan Capital | $300.0000 | $300 | Buy |
| 2024-10-10 | Needham | $320.00 | $320 | Buy |
| 2024-10-10 | RBC Capital | $300.00 | $300.00 | Outperform |
| 2024-09-19 | RBC Capital | $300.00 | $300.00 | Outperform |
| 2024-09-09 | Cantor Fitzgerald | $220.00 | $220.0000 | Neutral |
| 2024-09-04 | B of A Securities | $295.00 | $307.0000 | Buy |
| 2024-09-04 | RBC Capital | $300.00 | $300.00 | Outperform |
| 2024-08-30 | HC Wainwright & Co. | $400.00 | $400.00 | Buy |
| 2024-08-26 | JP Morgan | $248.00 | $280.0000 | Neutral |
| 2024-08-20 | HC Wainwright & Co. | $400.00 | $400.00 | Buy |
| 2024-08-16 | Goldman Sachs | $198.00 | $370.0000 | Buy |
| 2024-08-02 | Wells Fargo | $207.00 | $233.0000 | Equal-Weight |
| 2024-08-02 | RBC Capital | $265.00 | $300 | Outperform |
| 2024-08-02 | Raymond James | $242.0000 | $275.0000 | Outperform |
| 2024-08-02 | Goldman Sachs | $174.0000 | $198 | Neutral |
| 2024-08-02 | Barclays | $291.00 | $295.0000 | Overweight |
| 2024-08-02 | Canaccord Genuity | $357.00 | $366.0000 | Buy |
| 2024-08-02 | Citigroup | $291.00 | $342.0000 | Buy |
| 2024-08-02 | Needham | $275.00 | $320 | Buy |
| 2024-07-22 | Cantor Fitzgerald | $150.00 | $220.0000 | Neutral |
| 2024-07-12 | Morgan Stanley | $250.00 | $255 | Equal-Weight |
| 2024-07-08 | Canaccord Genuity | $283.00 | $357.0000 | Buy |
| 2024-07-03 | JP Morgan | $160.0000 | $248.0000 | Neutral |
| 2024-07-01 | Cantor Fitzgerald | $150.00 | $150.0000 | Neutral |
| 2024-06-28 | UBS | $253.0000 | $288.0000 | Buy |
| 2024-06-27 | RBC Capital | $250.00 | $265 | Outperform |
| 2024-06-27 | Stifel | $215.0000 | $295 | Buy |
| 2024-06-25 | Morgan Stanley | $164.0000 | $250.0000 | Equal-Weight |
| 2024-06-25 | Wells Fargo | $161.00 | $207.0000 | Equal-Weight |
| 2024-06-25 | RBC Capital | $235.00 | $250 | Outperform |
| 2024-06-25 | Barclays | $236.00 | $291.0000 | Overweight |
| 2024-06-25 | Evercore ISI Group | $210.0000 | $260.0000 | Outperform |
| 2024-06-25 | TD Cowen | $260.0000 | $282.0000 | Buy |
| 2024-06-25 | Leerink Partners | $138.0000 | $159.0000 | Market Perform |
| 2024-06-25 | B of A Securities | $248.0000 | $295 | Buy |
| 2024-06-25 | Citigroup | $227.00 | $291.0000 | Buy |
| 2024-06-24 | BMO Capital | $234.00 | $234 | Outperform |
| 2024-06-24 | HC Wainwright & Co. | $400.00 | $400.00 | Buy |
| 2024-06-24 | Needham | $200.00 | $275 | Buy |
| 2024-06-21 | Canaccord Genuity | $283.0000 | $283.0000 | Buy |
Alnylam Pharmaceuticals stock forecast for upcoming days
| Date | Price Target | Change |
|---|---|---|
| 2025-06-20 | $320.10 | 3.69% |
| 2025-06-23 | $342.79 | 7.09% |
| 2025-06-24 | $329.77 | -3.80% |
| 2025-06-25 | $332.04 | 0.69% |
| 2025-06-26 | $323.25 | -2.65% |
ALNY : Long term Alnylam Pharmaceuticals stock forecast for 2025 - 2026 - 2030 - 2035
Forecast for 2025 Jul. is $326.55 , for 2026 Jun. is $405.61 , for 2029 Jun. is $348.44 , for 2030 Jun. is $280.84 , for 2034 Jun. is $371.75 , and for 2035 Jun. is $377.22.
ALNY : Alnylam Pharmaceuticals stock forecast for 2025
| Date | Price Target | Change |
|---|---|---|
| 2025 Jul. | $326.55 | 5.78% |
| 2025 Aug. | $335.89 | 2.86% |
| 2025 Sep. | $341.23 | 1.59% |
| 2025 Oct. | $349.03 | 2.29% |
| 2025 Nov. | $357.49 | 2.42% |
| 2025 Dec. | $364.40 | 1.93% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2026
| Date | Price Target | Change |
|---|---|---|
| 2026 Jan. | $373.54 | 2.51% |
| 2026 Feb. | $382.42 | 2.38% |
| 2026 Mar. | $389.21 | 1.78% |
| 2026 Apr. | $394.15 | 1.27% |
| 2026 May. | $399.55 | 1.37% |
| 2026 Jun. | $405.61 | 1.52% |
| 2026 Jul. | $411.16 | 1.37% |
| 2026 Aug. | $415.59 | 1.08% |
| 2026 Sep. | $418.07 | 0.60% |
| 2026 Oct. | $417.96 | -0.03% |
| 2026 Nov. | $419.02 | 0.25% |
| 2026 Dec. | $425.13 | 1.46% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2027
| Date | Price Target | Change |
|---|---|---|
| 2027 Jan. | $425.68 | 0.13% |
| 2027 Feb. | $427.75 | 0.48% |
| 2027 Mar. | $428.18 | 0.10% |
| 2027 Apr. | $427.96 | -0.05% |
| 2027 May. | $428.86 | 0.21% |
| 2027 Jun. | $428.08 | -0.18% |
| 2027 Jul. | $427.82 | -0.06% |
| 2027 Aug. | $425.38 | -0.57% |
| 2027 Sep. | $421.65 | -0.88% |
| 2027 Oct. | $416.61 | -1.20% |
| 2027 Nov. | $410.32 | -1.51% |
| 2027 Dec. | $403.33 | -1.70% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2028
| Date | Price Target | Change |
|---|---|---|
| 2028 Jan. | $395.01 | -2.06% |
| 2028 Feb. | $383.94 | -2.80% |
| 2028 Mar. | $370.74 | -3.44% |
| 2028 Apr. | $356.38 | -3.87% |
| 2028 May. | $340.96 | -4.33% |
| 2028 Jun. | $324.94 | -4.70% |
| 2028 Jul. | $311.06 | -4.27% |
| 2028 Aug. | $302.70 | -2.69% |
| 2028 Sep. | $299.88 | -0.93% |
| 2028 Oct. | $301.77 | 0.63% |
| 2028 Nov. | $308.04 | 2.08% |
| 2028 Dec. | $319.83 | 3.83% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2029
| Date | Price Target | Change |
|---|---|---|
| 2029 Jan. | $337.91 | 5.65% |
| 2029 Feb. | $356.31 | 5.44% |
| 2029 Mar. | $366.65 | 2.90% |
| 2029 Apr. | $366.27 | -0.10% |
| 2029 May. | $358.64 | -2.08% |
| 2029 Jun. | $348.44 | -2.84% |
| 2029 Jul. | $337.73 | -3.07% |
| 2029 Aug. | $327.61 | -3.00% |
| 2029 Sep. | $319.22 | -2.56% |
| 2029 Oct. | $312.71 | -2.04% |
| 2029 Nov. | $307.78 | -1.58% |
| 2029 Dec. | $303.90 | -1.26% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2030
| Date | Price Target | Change |
|---|---|---|
| 2030 Jan. | $300.14 | -1.24% |
| 2030 Feb. | $295.24 | -1.63% |
| 2030 Mar. | $288.29 | -2.35% |
| 2030 Apr. | $280.46 | -2.72% |
| 2030 May. | $275.95 | -1.61% |
| 2030 Jun. | $280.84 | 1.77% |
| 2030 Jul. | $299.53 | 6.65% |
| 2030 Aug. | $331.21 | 10.58% |
| 2030 Sep. | $366.38 | 10.62% |
| 2030 Oct. | $391.08 | 6.74% |
| 2030 Nov. | $402.69 | 2.97% |
| 2030 Dec. | $400.55 | -0.53% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2031
| Date | Price Target | Change |
|---|---|---|
| 2031 Jan. | $389.25 | -2.82% |
| 2031 Feb. | $377.78 | -2.95% |
| 2031 Mar. | $368.55 | -2.44% |
| 2031 Apr. | $359.94 | -2.34% |
| 2031 May. | $352.23 | -2.14% |
| 2031 Jun. | $345.33 | -1.96% |
| 2031 Jul. | $340.44 | -1.42% |
| 2031 Aug. | $334.91 | -1.63% |
| 2031 Sep. | $330.18 | -1.41% |
| 2031 Oct. | $328.04 | -0.65% |
| 2031 Nov. | $326.82 | -0.37% |
| 2031 Dec. | $324.72 | -0.64% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2032
| Date | Price Target | Change |
|---|---|---|
| 2032 Jan. | $322.06 | -0.82% |
| 2032 Feb. | $319.96 | -0.65% |
| 2032 Mar. | $319.73 | -0.07% |
| 2032 Apr. | $321.55 | 0.57% |
| 2032 May. | $322.05 | 0.16% |
| 2032 Jun. | $317.97 | -1.27% |
| 2032 Jul. | $312.88 | -1.60% |
| 2032 Aug. | $308.75 | -1.32% |
| 2032 Sep. | $304.75 | -1.30% |
| 2032 Oct. | $300.74 | -1.32% |
| 2032 Nov. | $296.70 | -1.34% |
| 2032 Dec. | $292.34 | -1.47% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2033
| Date | Price Target | Change |
|---|---|---|
| 2033 Jan. | $287.03 | -1.82% |
| 2033 Feb. | $280.26 | -2.36% |
| 2033 Mar. | $272.77 | -2.67% |
| 2033 Apr. | $266.28 | -2.38% |
| 2033 May. | $261.57 | -1.77% |
| 2033 Jun. | $258.31 | -1.25% |
| 2033 Jul. | $256.54 | -0.68% |
| 2033 Aug. | $255.18 | -0.53% |
| 2033 Sep. | $249.79 | -2.11% |
| 2033 Oct. | $234.32 | -6.19% |
| 2033 Nov. | $211.54 | -9.72% |
| 2033 Dec. | $205.15 | -3.02% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2034
| Date | Price Target | Change |
|---|---|---|
| 2034 Jan. | $218.55 | 6.53% |
| 2034 Feb. | $247.98 | 13.47% |
| 2034 Mar. | $330.17 | 33.14% |
| 2034 Apr. | $368.86 | 11.72% |
| 2034 May. | $371.76 | 0.79% |
| 2034 Jun. | $371.75 | -0.00% |
| 2034 Jul. | $371.81 | 0.02% |
| 2034 Aug. | $363.38 | -2.27% |
| 2034 Sep. | $348.89 | -3.99% |
| 2034 Oct. | $350.58 | 0.49% |
| 2034 Nov. | $353.61 | 0.86% |
| 2034 Dec. | $357.70 | 1.16% |
ALNY : Alnylam Pharmaceuticals stock forecast for 2035
| Date | Price Target | Change |
|---|---|---|
| 2035 Jan. | $361.48 | 1.06% |
| 2035 Feb. | $363.99 | 0.69% |
| 2035 Mar. | $366.24 | 0.62% |
| 2035 Apr. | $368.36 | 0.58% |
| 2035 May. | $372.10 | 1.01% |
| 2035 Jun. | $377.22 | 1.38% |
Financial Data for Alnylam Pharmaceuticals stock
Frequently Asked Questions about Alnylam Pharmaceuticals stock forecast
Is Alnylam Pharmaceuticals a good long term stock?
From Alnylam Pharmaceuticals stock forecast , Alnylam Pharmaceuticals (ALNY) stock can be a good investment choice. According to AIPickup, the Alnylam Pharmaceuticals stock price forecast for 2025 Jul. is $326.548373015701 From Alnylam Pharmaceuticals stock forecast , Alnylam Pharmaceuticals (ALNY) stock can be a good investment choice. According to AIPickup, the Alnylam Pharmaceuticals stock price forecast for 2026 Jun. is $405.613341346451 From Alnylam Pharmaceuticals stock forecast , Alnylam Pharmaceuticals (ALNY) stock can be a good investment choice. According to AIPickup, the Alnylam Pharmaceuticals stock price forecast for 2029 Jun. is $348.442560166688 From Alnylam Pharmaceuticals stock forecast , Alnylam Pharmaceuticals (ALNY) stock cannot be a good investment choice. According to AIPickup, the Alnylam Pharmaceuticals stock price forecast for 2030 Jun. is $280.841091987886 From Alnylam Pharmaceuticals stock forecast , Alnylam Pharmaceuticals (ALNY) stock can be a good investment choice. According to AIPickup, the Alnylam Pharmaceuticals stock price forecast for 2034 Jun. is $371.753304330781 From Alnylam Pharmaceuticals stock forecast , Alnylam Pharmaceuticals (ALNY) stock can be a good investment choice. According to AIPickup, the Alnylam Pharmaceuticals stock price forecast for 2035 Jun. is $377.217454318115
Is Alnylam Pharmaceuticals stock overvalued?
Alnylam Pharmaceuticals (ALNY) stock is expected to go UP . Therefore, AIPickup would say that Alnylam Pharmaceuticals (ALNY) stock is NOT overvalued.
Will Alnylam Pharmaceuticals stock price go up?
Yes. The Alnylam Pharmaceuticals stock price forecast for 2026 Jun. is $405.613341346451
Is Alnylam Pharmaceuticals stock a good buy now?
Since closing price on 2025-06-17 is $308.709991455078 and forecast for 2026 Jun. is $405.61, Alnylam Pharmaceuticals stock is a good 1 year investment.
14 Days Historical Data for Alnylam Pharmaceuticals stock price
| Date | Close | Open | Low | High |
|---|---|---|---|---|
| ALNY stock price for 2025-05-29 | $292.90 | $287.65 | $284.73 | $293.22 |
| ALNY stock price for 2025-05-30 | $304.56 | $292.45 | $287.20 | $306.00 |
| ALNY stock price for 2025-06-02 | $306.09 | $303.10 | $299.52 | $307.19 |
| ALNY stock price for 2025-06-03 | $303.77 | $306.00 | $301.52 | $307.85 |
| ALNY stock price for 2025-06-04 | $305.31 | $303.22 | $302.33 | $308.93 |
| ALNY stock price for 2025-06-05 | $308.00 | $304.55 | $300.75 | $308.53 |
| ALNY stock price for 2025-06-06 | $300.83 | $309.00 | $300.27 | $310.22 |
| ALNY stock price for 2025-06-09 | $304.00 | $303.80 | $297.67 | $306.17 |
| ALNY stock price for 2025-06-10 | $302.46 | $303.81 | $301.34 | $308.89 |
| ALNY stock price for 2025-06-11 | $298.58 | $303.18 | $298.25 | $303.85 |
| ALNY stock price for 2025-06-12 | $304.67 | $300.48 | $295.82 | $307.48 |
| ALNY stock price for 2025-06-13 | $307.99 | $300.97 | $300.97 | $308.02 |
| ALNY stock price for 2025-06-16 | $308.78 | $306.45 | $302.32 | $309.63 |
| ALNY stock price for 2025-06-17 | $308.71 | $305.12 | $303.31 | $309.06 |